Dutch Regional Agency Targets Life Sciences Startups to Bridge Critical Funding Gap
Amsterdam, Friday, 3 April 2026.
ROM InWest is strategically increasing investments in Noord-Holland’s life sciences sector, addressing what industry insiders call the ‘Valley of Death’ - the critical period when promising health innovations struggle to secure funding between research and commercialization. The agency has already invested in breakthrough technologies including HeartEye’s wireless ECG recorder and Amplio Pharma’s enhanced rheumatoid arthritis treatment. This initiative positions the Netherlands to strengthen its role as a European life sciences hub, particularly crucial as healthcare IT adoption faces complex decision-making processes and medical device companies navigate strict certification requirements before generating revenue.
Strategic Investment Focus Addresses Market Gap
This news story focuses on healthtech and medical technology innovations. ROM InWest’s strategic investment approach specifically targets Life Sciences & Health startups across digital health, medical technology, and biotechnology sectors [1]. The initiative addresses a critical market failure where MedTech companies face what the industry terms a “Valley of Death” due to strict CE certification requirements, requiring significant investment before generating income [1]. Sara Schaafsma from ROM InWest explains the challenge: “Voor veel LSH‑startups is het extreem lastig om de juiste financiering te vinden om te kunnen groeien” [1]. The agency positions itself as a crucial bridge, functioning between early-stage development and the point where traditional lenders or commercial sales can provide sufficient revenue [1].
Breakthrough Medical Devices Show Investment Impact
ROM InWest’s investment strategy has already produced tangible results through breakthrough medical innovations. HeartEye, one of the agency’s portfolio companies, developed a wireless ECG recorder capable of producing a 12-channel electrocardiogram in under one minute [1]. The company successfully raised €1,675,000 with investments from ROM InWest, Pim Berger (co-founder of Schuberg Philis), and Mphasis for early detection of heart conditions [7]. Another significant investment involved Amplio Pharma, which developed NovoBioJect, an innovative drug that enhances the effectiveness of methotrexate, a standard rheumatoid arthritis treatment, while reducing side effects and delaying the need for expensive biological therapies [1]. Amplio Pharma secured over €1.3 million in funding from ROM InWest, Libertatis Ergo Holding, Amsterdam UMC Ventures Holding, and Innovatiefonds Noord-Holland [7].
Digital Health Faces Unique Adoption Challenges
Digital health companies encounter distinct obstacles in the healthcare sector, as demonstrated by companies like Healthplus.ai, which developed an artificial intelligence system for hospitals to predict postoperative complication risks for individual patients [1]. These companies face slower adoption rates due to healthcare’s complex IT landscapes and decision-making processes [1]. Despite these challenges, Healthplus.ai successfully raised €2.3 million for the accelerated rollout of PERISCOPE®, their AI system [7]. ROM InWest recognizes that software-based solutions appeal more to many investors because they offer greater scalability, stable and predictable revenue streams, faster development cycles, and easier adaptation compared to hardware solutions [1]. However, the healthcare sector’s conservative approach to technology adoption requires specialized investment strategies and longer development timelines.
Regional Economic Impact and Future Positioning
The Amsterdam Metropolitan Area represents one of Europe’s most promising regions for Life Sciences & Health and biotechnology, with 25% of Dutch LSH activity concentrated in the Amsterdam region [6]. The area hosts over 190 biotech companies and more than 20 leading research institutes, supporting 10,000 jobs in research and development and technology within the biotech sector [6]. ROM InWest’s investment strategy directly contributes to maintaining healthcare affordability and accessibility in the Netherlands while strengthening Noord-Holland’s economic position [1]. The agency estimates that treating infections costs an average hospital €35 million annually, highlighting the significant economic impact potential of successful medical innovations [1]. By bridging the funding gap between research and commercialization, ROM InWest aims to ensure that impactful innovations reach clinical practice, supporting both patient outcomes and regional economic development [1].